ArticleClinical and experimental medicine2025
Treatment of refractory non-small cell lung cancer with combined infusion of modified CIK cells and PD1 antibody: safety and efficacy.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Translational landscape of cytokine-induced killer cell therapy: an analysis based on the Informa database.Journal for immunotherapy of cancer · 2026Article
- Clinical application of cytokine-induced killer cells in cancer immunotherapy.Cancer cell international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the safety and efficacy of modified CIK cells combined with PD-1 antibody in the treatment of refractory non-small cell lung cancer (NSCLC). Fifteen patients with refractory NSCLC who were treated in our hospital were recruited for this clinical study from January 2015 to December 2020. All patients had disease progression after completing routine treatment. Two of 12 patients achieved a partial remission, 6 had stable disease, and 4 had progressive disease. No serious side effects occurred. The percentage of T helper and NKT-like cells in patients increased significantly after immunotherapy (P < 0.05). In addition, the anti-tumor cytokines (IL-2 and INF-γ) increased significantly (P < 0.05). Although the anti-inflammatory cytokine, IL-10, did not change markedly after immunotherapy (P > 0.05), the Karnofsky Performance Scale was improved. Umbilical cord blood mononuclear cells can be induced into NKT-like cells. Induced NKT-like cells had powerful cytotoxicity against tumor cell lines in vitro when combined with PD1 antibody. Immunotherapy also had a significant therapeutic effect on refractory NSCLC with no serious side effects in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.